Αποτελέσματα Αναζήτησης
Foundational therapy is metformin and comprehensive lifestyle management (including weight management and physical activity) Metformin is the preferred initial glucose lowering medication for most people with T2D. This recommendation is based on the efficacy, safety, tolerability, and extensive clinical.
4 Δεκ 2020 · These estimates are based on ADAG data of ∼2,700 glucose measurements over 3 months per A1C measurement in 507 adults with type 1, type 2, or no diabetes. The correlation between A1C and average glucose was 0.92 ( 6 , 7 ).
The combination of lifestyle intervention and obesity medications can be highly effective as demonstrated in clinical trials with phentermine/topiramate ER (59) and liraglutide 3 mg (74), for example, which reduced progression to diabetes by ~80% over the 2- to 3-year course of these studies.
Common sliding scale regimens: Long-acting insulin (glargine/detemir or NPH), once or twice a day with short acting insulin (aspart, glulisine, lispro, Regular) before meals and at bedtime. Long-acting insulin (glargine/detemir or NPH), given once a day. Regular and NPH, given twice a day.
The 2020 algorithm for management of persons with type 2 diabetes includes sections on lifestyle therapy, a complications-centric model for care of persons with overweight/obesity, prediabetes, management of hypertension and dyslipidemia (risk factors for atherosclerotic cardiovascular disease), glucose control with medications, insulin therapy
Optimal A1C is ≤6.5%, or as close to normal as is safe and achievable. Therapy choices are patient centric based on A1C at presentation and shared decision-making. Choice of therapy reflects ASCVD, CHF, and renal status. Comorbidities must be managed for comprehensive care.
• Type 1 and type 2 diabetes: early meticulous glucose control appears to prevent CVD many years later (“metabolic memory” and “legacy effect”) “The ADA recommends that a reasonable A1C goal for many nonpregnant adults with type 2 diabetes is less than 7 percent based on the available evidence to date
